Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

SYK.NYSE

Stryker

Healthcare | Medical Devices

Medical technology company offering innovative products and services in orthopedics, medical and surgical equipment, and neurotechnology.

Flagship Insight

Why Surgical Robotics Moats Face Valuation Gravity in Tight Liquidity Regimes

There is high consensus that structural demographic tailwinds and surgical robotics lock-in defend long-term earnings, but sharp divergence exists regarding near-term valuation vulnerability. While some anticipate seamless platform expansion, others warn that restrictive capital costs and hospital budget constraints will trigger multiple compression.

Forecast TimelineUpdated On Jul 02 2026

Stryker (SYK) Stock Forecast and AI Rating

Recommendation

No Action - Keep Monitoring

Only one horizon is positive; wait for broader confirmation.

2027

1-Year

NEUTRAL

$332

+1.7%

+4.2% IF INCL. DIVS

2029

3-Year

N/A

$400

+27%

2031

5-Year

BUY

$477

+46%

+57% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The core investment thesis centers on a high-conviction transition from a legacy medical hardware manufacturer to a high-margin digital surgical platform. While the underlying business compounds relentlessly due to inelastic demographic demand and the Mako robotic ecosystem's high switching costs, the equity faces near-term valuation headwinds. In a restrictive monetary regime, the current premium multiple is highly vulnerable to compression as hospital capital budgets tighten, creating a divergence between operational execution and stock performance. Professional allocators must balance long-term structural dominance against near-term multiple compression risks.

Key insights

The Mako robotic platform establishes an insurmountable data and consumable moat, locking in high-margin recurring revenue streams.
Restrictive monetary policy and hospital margin pressure elongate capital equipment sales cycles, temporarily slowing new system placements.
Pristine free cash flow generation exceeding fifteen percent margins insulates the enterprise from refinancing risks and funds opportunistic acquisitions.
Recent large-scale acquisitions expand the addressable market into high-growth vascular segments but introduce integration and goodwill impairment risks.
Valuation multiple compression remains the primary risk, as a premium multiple faces gravity under elevated risk-free rates.
Forensic scrutiny is warranted following recent executive accounting turnover and cyber-remediation costs to confirm internal control integrity.
Tactical positioning suggests accumulating shares during multiple-driven drawdowns rather than chasing peak-cycle valuations.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Stryker quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Stryker.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$306.95	$320.28	$342.87	$736.09
Quarter 2+6M	Jan 02, 2027	$294.67	$321.11	$356.58	$724.14
Quarter 3+9M	Apr 02, 2027	$279.94	$321.10	$363.71	$713.57
Quarter 4+1Y	Jul 02, 2027	$285.53	$325.61	$359.93	$723.38
Quarter 5+15M	Oct 02, 2027	$276.97	$331.93	$370.73	$716.61
Quarter 6+18M	Jan 02, 2028	$271.43	$342.57	$392.94	$738.34
Quarter 7+21M	Apr 02, 2028	$285.00	$349.84	$404.73	$746.91
Quarter 8+2Y	Jul 02, 2028	$279.30	$357.74	$420.92	$771.93
Quarter 9+27M	Oct 02, 2028	$279.30	$359.72	$429.33	$782.73
Quarter 10+30M	Jan 02, 2029	$290.47	$373.68	$455.09	$807.31
Quarter 11+33M	Apr 02, 2029	$299.19	$382.16	$473.30	$822.72
Quarter 12+3Y	Jul 02, 2029	$305.17	$390.70	$459.10	$846.10
Quarter 13+39M	Oct 02, 2029	$314.33	$399.90	$482.05	$852.53
Quarter 14+42M	Jan 02, 2030	$326.90	$415.43	$510.98	$882.91
Quarter 15+45M	Apr 02, 2030	$333.44	$424.27	$526.31	$900.46
Quarter 16+4Y	Jul 02, 2030	$326.77	$430.24	$547.36	$922.67
Quarter 17+51M	Oct 02, 2030	$339.84	$437.40	$558.31	$935.91
Quarter 18+54M	Jan 02, 2031	$350.03	$451.64	$586.22	$952.30
Quarter 19+57M	Apr 02, 2031	$360.54	$462.80	$603.81	$976.28
Quarter 20+5Y	Jul 02, 2031	$367.75	$476.77	$627.96	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the structural mispricing of the capital equipment cycle and the duration risk of a premium multiple in a high-rate environment. While the crowd prices the asset as a physical hardware manufacturer, the true value lies in its transition to a closed-loop digital operating system for the surgical suite, which generates high-margin recurring software and consumable revenue. However, the market is overly complacent about valuation gravity. A premium multiple cannot withstand the mechanical pressure of elevated risk-free rates and tightening hospital budgets. Furthermore, the crowd underestimates the near-term margin compression from supply chain friction, tariff headwinds, and the forensic risks associated with sudden executive accounting turnover following a major cyber incident.

Advisor Disagreement

The primary disagreement across reports centers on the duration and severity of near-term valuation and operational headwinds. Some perspectives assume a rapid, V-shaped recovery from the Q1 cyber incident and tariff drags, arguing that demographic demand will seamlessly absorb near-term friction. Conversely, more cautious views emphasize the structural risks of multiple compression in a high-rate environment, the potential internal control weaknesses signaled by sudden executive accounting turnover, and the risk of integration indigestion from recent multi-billion-dollar acquisitions. These differing horizons and risk weightings drive highly divergent near-term price projections.

Financial Reviews by iPulse AI

Earnings and financials

The company's financial engine is incredibly strong, highlighted by massive revenue growth and exceptional cash generation. In 2025, sales reached over $25 billion, and free cash flow jumped to over $4 billion, showing that the business is highly efficient at turning sales into actual cash. However, there is a clear disagreement about the near-term outlook. Some experts point out that a recent cyberattack caused a temporary slowdown in early 2026, which might signal deeper issues, while others believe this is just a short-term bump that will quickly clear up as delayed surgeries are rescheduled. Overall, while the long-term trend is supported by an aging population that needs medical devices, investors should watch whether the company can maintain its high-quality earnings without relying too heavily on buying other companies to fuel its growth.

Profitability and margins

The company boasts elite profitability, with gross margins consistently holding around 64%, reflecting its immense pricing power over hospitals. However, operating margins have recently faced some pressure, dipping slightly due to supply chain issues, rising material costs, and cyberattack recovery expenses. There is a clear clash of opinions regarding the future of these margins. Optimistic views suggest that as high-margin software and robotic consumables become a larger part of the sales mix, profit margins will expand significantly. On the other hand, cautious observers warn that rising inflation, government price controls, and hospital budget cuts will limit margin growth. Because the stock is currently priced for absolute perfection, even a minor slip in profitability could lead to a sharp drop in the stock price.

Balance sheet and leverage

The company's balance sheet is a financial fortress, built to withstand economic storms and high interest rates. With low debt relative to its size and excellent interest coverage, the company has virtually zero risk of running into financial trouble. This financial safety is a massive advantage in today's tight credit environment, where smaller competitors are struggling to survive. There is strong agreement that this pristine balance sheet gives the company the unique ability to fund its own growth and make smart acquisitions without needing to borrow expensive money. While the company did take on more debt recently to fund a major acquisition, its massive cash reserves and steady cash flow ensure it can easily manage its debt while continuing to pay dividends and support its stock.

Capex and investment intensity

The company operates with outstanding capital efficiency, spending only about 3% of its revenue on physical factories and equipment. Instead of building expensive plants, it focuses its heavy spending on research and development to constantly improve its robotic surgery systems and software. This smart, asset-light approach allows the company to generate massive amounts of free cash flow. However, opinions differ on the company's aggressive strategy of buying other businesses. Some view these multi-billion-dollar acquisitions as a brilliant way to expand into new medical fields, while others worry that the heavy spending on buyouts hides a slowdown in the company's core business and could hurt long-term returns if the integration of these new businesses fails to deliver the expected results.